Skip to main content
Equibles

RDY · Dr Reddys Laboratories Ltd · Financials

Track RDY — free

Use RDY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.15 +0.40 (+2.91%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$11.73B
Shares
833.07M
Volume · Oct 28 4.47M Avg daily vol (3M) 2.92M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
335.93B +3.2%
FY2026 Revenue FY2016–FY2026
Net Income
42.85B -24.2%
FY2026 Net Income FY2016–FY2026
Gross Margin
52.77% -5.7pp
FY2026 Gross Margin FY2016–FY2026
Operating Margin
15.05% -7pp
FY2026 Operating Margin FY2016–FY2026
Diluted EPS
51.42 -24.1%
FY2026 Diluted EPS FY2016–FY2026
Operating Cash Flow
56.76B +22.2%
FY2026 Operating Cash Flow FY2016–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
INR 1.84B — — — — — — — — — —
INR 12.62B 10.51B 9.58B 8.62B 8.15B 8.53B 8.64B 8.36B 11.71B 11.28B 10.25B
USD/shares $0.55 $0.79 $0.80 $0.66 $0.37 $0.28 $0.31 $0.33 $0.18 — —
USD/shares $0.55 $0.79 $0.80 $0.66 $0.37 $0.30 $0.31 $0.33 $0.18 — —
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2026: 17.36B in buybacks, 52.65B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Borrowings 2026-03-31 INR 18,206,000,000 20-F filed 2026-05-29
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term borrowings
INR 6,003,000,000
Noncurrent long-term borrowings
INR 12,203,000,000
Short-term borrowings
INR 59,135,000,000
Current portion of long-term borrowings 2026-03-31 USD 64,000,000 20-F filed 2026-05-29
Lease liabilities 2026-03-31 INR 5,436,000,000 20-F filed 2026-05-29
Noncurrent long-term borrowings 2026-03-31 USD 130,000,000 20-F filed 2026-05-29
Short-term borrowings 2026-03-31 USD 630,000,000 20-F filed 2026-05-29
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1135951 CUSIP 256135203 13F (30d) 56 filings 51 filers Visit website Investor relations